Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
ZOE.DE
BUYZoetis Inc. · Healthcare · United States · $32.0B · Avg Vol: $127K/d
COMPANY DESCRIPTION
Zoetis Inc. is the global leader in the animal health industry, discovering, developing, and manufacturing medicines, vaccines, and diagnostic products for livestock and companion animals. Its competitive moat is exceptionally strong, driven by direct-to-veterinarian sales relationships, diverse product portfolios, and high customer loyalty. The company is a dominant market leader with high margins and low exposure to generic competition compared to human health.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1B | 8.5B | 9.3B | 9.5B | 5.4% | 9.5B | 9.8B | 10.1B | 3.5% |
| EPS | 4.51 | 5.08 | 5.47 | 6.03 | 10.2% | 6.10 | — | — | — |
| Shares | 463.8M | 458.4M | 448.5M | 424.9M | -8.4% | 419.2M | — | — | — |
| Debt | 8.1B | 6.8B | 6.7B | 9.2B | 4.5% | 9.3B | — | — | — |
| Equity | 4.4B | 5.0B | 4.8B | 3.3B | -8.9% | — | — | — | — |
| Op CF | 1.9B | 2.4B | 3.0B | 2.9B | 14.9% | 2.8B | — | — | — |
| Inv CF | -883.0M | -777.0M | -315.0M | -748.0M | — | — | — | — | — |
| Fin CF | -904.0M | -3.1B | -2.7B | -1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZOE.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZOE.DE | Zoetis Inc.(you) | $32.0B | 66 | BUY |
| ELAN | Elanco Animal Health Incorporated | $12.4B | 74 | BUY |
| VTRS | Viatris Inc. | $20.1B | 87 | STRONG BUY |
| UTHR | United Therapeutics Corporation | $26.3B | 95 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $17.7B | 91 | STRONG BUY |
| LQDA | Liquidia Corporation | $7.7B | 54 | HOLD |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.7B | 64 | HOLD |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.7B | 87 | STRONG BUY |
| LNTH | Lantheus Holdings, Inc. | $6.8B | 93 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.8B | 91 | STRONG BUY |
Peer medians: ROE -25.7% · P/E 27.9x · Gross margin 50.4%